Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

Worse TAVI and M-TEER Outcomes Seen With Low-Volume Operators

News Daily News

Worse TAVI and M-TEER Outcomes Seen With Low-Volume Operators

Michael O'Riordan

January 22, 2026

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

Cath Lab Attire: ‘Dress Up and Shut Up’ or Time for a Change?

News Opinion Conversations in Cardiology

Cath Lab Attire: ‘Dress Up and Shut Up’ or Time for a Change?

March 28, 2025

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

Early Actions by Trump Administration Sow Uncertainty for CV Research

News Daily News

Early Actions by Trump Administration Sow Uncertainty for CV Research

January 30, 2025

All Eyes on PCI—Should Patients’ Family Members Watch Cases?

News Opinion Conversations in Cardiology

All Eyes on PCI—Should Patients’ Family Members Watch Cases?

December 19, 2024

Reimbursement Issues Seem to Be Holding Renal Denervation Back

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

December 19, 2024

Lessons From the Initial FDA Trials

Presentation NY Valves 2024

Lessons From the Initial FDA Trials

Presenter: David J. Cohen

June 06, 2024

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

News Daily News

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

May 09, 2024

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Medicare Data on AMICS Too Muddied for Firm Conclusions on Impella

News Daily News

Medicare Data on AMICS Too Muddied for Firm Conclusions on Impella

June 21, 2023

Top 10 Interventional Cardiology Trials You Need to Know (and Why)

Presentation Fellows 2023

Top 10 Interventional Cardiology Trials You Need to Know (and Why)

Presenter: David Cohen

May 11, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

News Conference News STS 2023

Large Medicare Analysis Reopens Debate Over Multivessel Revascularization

Yael L. Maxwell

January 24, 2023

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Presentation TCT 2022

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Presenter: David J. Cohen

September 17, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.